ClinicalTrials.gg
CompletedNCT01675635Updated Feb 26, 2018Results posted

OxyNorm Capsules in Post-Operative Pain Study

A Phase 3 interventional study of OxyNorm Capsules and Morphine tablet in Postoperative Pain, sponsored by Mundipharma (China) Pharmaceutical Co. Ltd. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-02-26.

Sponsored by Mundipharma (China) Pharmaceutical Co. Ltd (part of Mundipharma) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 32 studies testing oxycodone in Pain, Postoperative — 5 open to participants now, 7 under way, 1 of them phase 3. Oxycodone · Pain, Postoperative.

Enrollment
8th of 32
240 · median 126
Started
2011
with 2 others
Phase 3
4 of 32
1 open now
Registered
8th of 32
by date
Lead sponsor
2 of 32
Mundipharma (China) Pharmaceutical Co. Ltd

Among the 32 studies testing oxycodone in Pain, Postoperative, this one is the 8th largest by enrollment, is one of 3 that started in 2011, is one of 4 in phase 3, and was the 8th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,231 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

5 of the 32 studies testing oxycodone in Pain, Postoperative are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About oxycodone

Oxycodone: first FDA approval 1950 (PERCODAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 679 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing oxycodone in Pain, Postoperative, or all of them as a file.
02

Study summary

The efficacy and safety of oxycodone capsules compared with morphine tablets in hospitalized patients with moderate to severe pain following surgery.

Read the detailed description

To evaluate the efficacy and safety of oxycodone immediate-release capsules compared with morphine immediate-release tablets in hospitalized patients with moderate to severe pain following surgery.

03

Conditions studied

  • Postoperative Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients of either sex aged 18 to 80 years inclusive.
  2. Patients who have given written to participate in the study.
  3. Able and willing to communicate with the investigator and his/her staff.
  4. Free of anesthesia as assessed through question and answer interaction with nurse at which time oral medication is indicated.
  5. Reporting "moderate" or "severe" pain (VAS ≥ 4) related to surgery and requesting analgesics for pain relief.

Exclusion criteria

Exclusion Criteria:

  1. Patients have developed tolerance to or dependence on narcotic analgesics and/or alcohol.
  2. Patients with ASA ≥ 3 .
  3. Have any concomitant medical condition that would be adversely affected by analgesics or confound the quantification of analgesia, or could affect the absorption, metabolism or excretion of the study drugs in any fashion.
  4. Have known to any of the study medications or related agents.
  5. Have taken analgesic medications within three hours (wash-out) prior to dosing.
  6. Have developed complications from the surgical procedure that would confound the study.
  7. Have a history of severe iatrogenic adverse experiences.
  8. Mothers nursing their infant during the 24 hours following study drug administration, or pregnant women.
  9. Patient with Nothing Per Os (NPO) as stated in patient's chart or physician's order.
  10. Surgery in patients with epidural anesthesia
  11. Patients with Severe impairment of liver at preoperative stage (, AST ≥ 1.5 times upper limit) and abnormal renal function.
  12. Patients with medical history of recovering from abnormal surgery anesthesia.
  13. Patients with medical history of hypertension (Systolic blood pressure ≥ 180Hg, Diastolic blood pressure 110Hg).
  14. Patients with shock.
  15. Patients with .
  16. According to investigator to determine, patients are in addition the inclusion criteria and exclusion criteria for any other reason than not suitable in this study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
240 participants (actual)

Study arms

  • Experimental
    OxyNorm Capsules

    To determine the efficacy and safety of OxyNorm Capsules.

    Drug: OxyNorm Capsules

  • Active comparator
    Morphine tablet

    To determine the efficacy and safety of Morphine tablet.

    Other: Morphine tablet

Interventions

  • dosage:5mg,l0mg and 20mg dosage form:capsule frequency:every 6h, duration:24 hours

    Also known as: OxyNorm

  • OtherMorphine tablet

    dosage: 10mg and 20mg; dosage form: tablet; frequency: every 6h; duration: 24 hours.

    Also known as: Morphine

06

What researchers measure

Primary outcomes

  1. Visual Analogue Scale (VAS) in Resting Stage at 6hour (6hour±20 Minutes After Administration of First Dose)

    To measure resting VAS at 6h(±20min) after administration of first dose, assessing the intensity of pain, and to conduct inter-group comparison Visual Analogue Scale 0 10 20 30 40 50 60 70 80 90 100 0 means no pain; 100 means pain as bad as you can image at resting stage

    Time frame: Baseline and 6h (±20min)

Secondary outcomes

  1. VAS in Both Resting and Coughing Stage at 0.5h, 2h and 24h After Administration of First Dose

    To measure the resting and coughing VAS as 0.5h (±5min), 2h (±10min) and 24h (±20min) after administration of first dose, assessing the intensity of pain and to conduct inter-group comparison

    Time frame: Baseline,0.5h (±5min), 2h (±10min) and 24h (±20min)

  2. The Use of Rescue Analgesics During the 24-hour Observation Period

    To calculate the subject who used rescue analgesics during the 4 dose interval within the 24-hour observation period and to conduct inter-group comparison

    Time frame: 24 hours after the first dose.

  3. VAS in Coughing Stage at 6h (6h±20min After Administration of First Dose)

    To measure coughing VAS at 6h (±20min) after administration of first dose, assessing the intensity of pain, and to conduct inter-group comparison Visual Analogue Scale 0 10 20 30 40 50 60 70 80 90 100 0 means no pain; 100 means pain as bed as you can image applicable for both resting and coughing stage

    Time frame: Baseline and 6h (±20min)

  4. Sleeping Quality Assessment

    To assess Sleeping quality assessment during 24 hours after administration of first dose and to conduct inter-group comparison Sleeping quality scale 1. Very Good 2. Good 3. Fair 4. Bad 5. Very Bad

    Time frame: 24 hours after administration of first dose

  5. Satisfaction With Pain Control

    To assess the Satisfaction with pain control during 24 hours after administration of first dose and to conduct inter-group comparison 1. Very Satisfied 2. Satisfied 3. Fair 4. Not Satisfied 5. Not Satisfied at all

    Time frame: 24 hours after administration of first dose

  6. Comparison of the Total Amount of Study Drugs Used During the 24 Hours

    To calculate the total amount of study drugs used during the 24 hours and to conduct inter-group comparison The study drug administration is average 6 hours,so the maximal is use 4 times in 24 hours. The investigate to evaluate if the subject need to take the 2nd, 3rd and 4th dose after the mandatory the 1st dose.

    Time frame: 24 hours after administration of first dose

07

Results

Posted Feb 26, 2018

Participant flow

This study is a randomized, double blind, double dummy, multicenter, parallel group, comparative study to compare the efficacy and safety of oxycodone capsule versus morphine tablet. The subject recruited from hospitalized patients poor with moderate to severe pain following surgery. The duration of the study from 2011 Jul to 2011 Dec.

Participant flow — Overall Study
MilestoneOxyNorm CapsulesMorphine Tablet
Started117117
Completed117117
Not completed00

Outcome measures

PrimaryVisual Analogue Scale (VAS) in Resting Stage at 6hour (6hour±20 Minutes After Administration of First Dose)

To measure resting VAS at 6h(±20min) after administration of first dose, assessing the intensity of pain, and to conduct inter-group comparison Visual Analogue Scale 0 10 20 30 40 50 60 70 80 90 100 0 means no pain; 100 means pain as bad as you can image at resting stage

Time frame:
Baseline and 6h (±20min)
Reported as:
Mean · units on a scale
Visual Analogue Scale (VAS) in Resting Stage at 6hour (6hour±20 Minutes After Administration of First Dose)
units on a scaleOxyNorm CapsulesMorphine Tablet
baseline of Visual Analogue Scale46.21 ± 9.5345.48 ± 7.94
6th hours Visual Analogue Scale20.21 ± 15.6619.94 ± 15.68
SecondaryVAS in Both Resting and Coughing Stage at 0.5h, 2h and 24h After Administration of First Dose

To measure the resting and coughing VAS as 0.5h (±5min), 2h (±10min) and 24h (±20min) after administration of first dose, assessing the intensity of pain and to conduct inter-group comparison

Time frame:
Baseline,0.5h (±5min), 2h (±10min) and 24h (±20min)
Reported as:
Mean · units on a scale
VAS in Both Resting and Coughing Stage at 0.5h, 2h and 24h After Administration of First Dose
units on a scaleOxyNorm CapsulesMorphine Tablet
Resting baseline of Visual Analogue Scale46.21 ± 9.5345.48 ± 7.96
Resting visual analogue scale before first dose46.21 ± 9.5345.48 ± 7.96
Resting VAS 0.5 hour after first dose29.87 ± 13.5929.80 ± 12.39
Resting VAS 2 hours after first dose20.58 ± 14.4020.89 ± 12.70
Resting VAS 24 hours after first dose9.73 ± 12.529.75 ± 11.19
Coughing baseline of Visual Analogue Scale55.16 ± 12.1553.91 ± 10.39
Coughing visual analogue scale before first dose55.20 ± 12.1253.91 ± 10.39
Coughing VAS 0.5 hour after first dose39.21 ± 16.5637.96 ± 13.61
Coughing VAS 2hours after first dose29.68 ± 17.9129.30 ± 13.76
Coughing VAS 24hours after first dose17.11 ± 13.5116.27 ± 12.58
SecondaryThe Use of Rescue Analgesics During the 24-hour Observation Period

To calculate the subject who used rescue analgesics during the 4 dose interval within the 24-hour observation period and to conduct inter-group comparison

Time frame:
24 hours after the first dose.
Reported as:
Count of participants · Participants
The Use of Rescue Analgesics During the 24-hour Observation Period
ParticipantsOxyNorm CapsulesMorphine Tablet
First dose interval(0-6h)75
Second dose interval(7-12h)82
Third dose interval(13-18)10
Fourth dose interval(19-24h)32
SecondaryVAS in Coughing Stage at 6h (6h±20min After Administration of First Dose)

To measure coughing VAS at 6h (±20min) after administration of first dose, assessing the intensity of pain, and to conduct inter-group comparison Visual Analogue Scale 0 10 20 30 40 50 60 70 80 90 100 0 means no pain; 100 means pain as bed as you can image applicable for both resting and coughing stage

Time frame:
Baseline and 6h (±20min)
Reported as:
Mean · units on a scale
VAS in Coughing Stage at 6h (6h±20min After Administration of First Dose)
units on a scaleOxyNorm CapsulesMorphine Tablet
Visual Analogue Scale of baseline coughing55.16 ± 12.1553.91 ± 10.39
Visual Analogue Scale after 6hours coughing28.81 ± 17.5828.15 ± 16.79
SecondarySleeping Quality Assessment

To assess Sleeping quality assessment during 24 hours after administration of first dose and to conduct inter-group comparison Sleeping quality scale 1. Very Good 2. Good 3. Fair 4. Bad 5. Very Bad

Time frame:
24 hours after administration of first dose
Reported as:
Count of participants · Participants
Sleeping Quality Assessment
ParticipantsOxyNorm CapsulesMorphine Tablet
Very Good3136
Good3848
Fair3826
Bad52
Very Bad11
SecondarySatisfaction With Pain Control

To assess the Satisfaction with pain control during 24 hours after administration of first dose and to conduct inter-group comparison 1. Very Satisfied 2. Satisfied 3. Fair 4. Not Satisfied 5. Not Satisfied at all

Time frame:
24 hours after administration of first dose
Reported as:
Count of participants · Participants
Satisfaction With Pain Control
ParticipantsOxyNorm CapsulesMorphine Tablet:
Very Satisfied3843
Satisfied5458
Fair1912
Not Satisfied20
Not Satisfied at all00
SecondaryComparison of the Total Amount of Study Drugs Used During the 24 Hours

To calculate the total amount of study drugs used during the 24 hours and to conduct inter-group comparison The study drug administration is average 6 hours,so the maximal is use 4 times in 24 hours. The investigate to evaluate if the subject need to take the 2nd, 3rd and 4th dose after the mandatory the 1st dose.

Time frame:
24 hours after administration of first dose
Reported as:
Mean · mg
Comparison of the Total Amount of Study Drugs Used During the 24 Hours
mgOxyNorm CapsulesMorphine Tablet
Comparison of the Total Amount of Study Drugs Used During the 24 Hours18.50 ± 10.3739.82 ± 21.79

Adverse events

Collected over The protocol requires safety follow up until 24 hours after the last study medication dosing. So the longest time one subject in the study is 48 hours after the 1st study medication doing, include taking full of the 4 times dosing(intotal 24 hours) following by safety follow up for 24 hours.. Non-serious events are listed at a 0.0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OxyNorm Capsules0/117 (0%)0/117 (0%)35/117 (29.9%)
Morphine Tablet0/117 (0%)0/117 (0%)35/117 (29.9%)
Most frequent other events
Showing 10 of 27
Most frequent other events
EventOxyNorm CapsulesMorphine Tablet
NauseaGastrointestinal disorders15/11714/117
VomitingGastrointestinal disorders7/1177/117
DizzinessNervous system disorders7/1176/117
abdominal distensionGastrointestinal disorders3/1175/117
blood glucose increaseBlood and lymphatic system disorders1/1173/117
backacheMusculoskeletal and connective tissue disorders2/1170/117
postoperative infectionInfections and infestations2/1172/117
headacheNervous system disorders2/1171/117
serum creatinine increaseBlood and lymphatic system disorders2/1172/117
leucocyte count increaseBlood and lymphatic system disorders0/1172/117

Baseline characteristics

Age, Continuous
Age, Continuous(years)OxyNorm CapsulesMorphine TabletTotal
Mean43.44 ± 11.0643.29 ± 10.5343.37 ± 10.77
Sex: Female, Male
Sex: Female, Male(Participants)OxyNorm CapsulesMorphine TabletTotal
Female10193194
Male162440
Race (NIH/OMB)
Race (NIH/OMB)(Participants)OxyNorm CapsulesMorphine TabletTotal
American Indian or Alaska Native000
Asian116117233
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported101
Region of Enrollment
Region of Enrollment(Participants)OxyNorm CapsulesMorphine TabletTotal
China117117234
Electrocardiogram test
Electrocardiogram test(Participants)OxyNorm CapsulesMorphine TabletTotal
normal8876164
abnormal, not clinical significant293463
abnormal,clinical significant055
America Society of Anesthesiologist classification
America Society of Anesthesiologist classification(Participants)OxyNorm CapsulesMorphine TabletTotal
P1(Class I)6157118
P2(Class II)5660116
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of Jun 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2018, 5 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2012
First posted
Aug 30, 2012
Start
Jul 2011
Primary completionActual
Jun 2012
CompletionActual
Jul 2012
Results first posted
Feb 26, 2018
Last update
Feb 26, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01675635
Responsible party
Sponsor
First posted
Aug 30, 2012
Start date
Jul 2011
Primary completion
Jun 2012
Completion
Jul 2012
Results posted
Feb 26, 2018
Last update
Feb 26, 2018

Study contacts

XinMin Wu, Prof.
principal investigator · Peking University 1st Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxycodone

Start the discussion